Skip Nav Destination
Issues
1 June 2016
-
Cover Image
Cover Image
There has been limited progress in obtaining a comprehensive genomic analysis of colorectal adenomas and at-risk mucosa. Therefore, exome sequencing efforts focusing on the characterization of the evolution from normal tissue to carcinoma via greater resolution of molecular changes at the inflection point of premalignant lesions are critical to identify novel candidate genes involved in intestinal carcinogenesis that could serve as biomarkers and drug targets for future chemoprevention trials. The cover is displaying a circos plot summarizing the genomic landscape of 25 colorectal adenomas from patients diagnosed with familial adenomatous polyposis. The outer ideogram runs clockwise from chromosome 1 to 22. The tracks from outside going in present stop gains and frameshift mutations (green), nonsynonymous and indels that produce non-frameshift mutations (red), synonymous mutations (purple), allelic frequencies of detected somatic mutations (light purple), and percentage of adenomas in the cohort that harbor somatic alterations (blue). The genes displayed outside the chromosomes harbor somatic mutations classified as damaging. Genes in red have been found recurrently mutated. Finally, inner ideograms display copy number profiles in different shades of green: amplification (light), copy-neutral LOH (dark), and deletions (medium) are depicted from the outside to inside. See the article by Borras and colleagues (beginning on page 417) for more information. - PDF Icon PDF LinkTable of Contents
ISSN 1940-6207
EISSN 1940-6215
Issue Sections
Research Articles
Genomic Landscape of Colorectal Mucosa and Adenomas
Ester Borras; F. Anthony San Lucas; Kyle Chang; Ruoji Zhou; Gita Masand; Jerry Fowler; Maureen E. Mork; Y. Nancy You; Melissa W. Taggart; Florencia McAllister; David A. Jones; Gareth E. Davies; Winfried Edelmann; Erik A. Ehli; Patrick M. Lynch; Ernest T. Hawk; Gabriel Capella; Paul Scheet; Eduardo Vilar
Elevated Levels of Urinary PGE-M Are Found in Tobacco Users and Indicate a Poor Prognosis for Oral Squamous Cell Carcinoma Patients
Vikram D. Kekatpure; Naveen BS; Hanhan Wang; Xi Kathy Zhou; Chandramohan Kandasamy; Sumsum P. Sunny; Amritha Suresh; Ginger L. Milne; Moni Abraham Kuriakose; Andrew J. Dannenberg
Advertisement
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.